STAAR Surgical Company (STAA) Earnings Call Transcripts

STAAR Surgical Company's Latest Earnings Call - May 27, 2026

In Q1 2026, STAAR Surgical Company (STAA:US) reported revenue of $47.4 million, driven by strong demand for EVO ICLs, particularly in China, marking a significant recovery from prior year declines. The company achieved a year-over-year growth of 22% in the U.S. market, surpassing $6 million in quarterly sales for the first time. Management maintained a cautious stance on future guidance, citing the need for predictability amid macroeconomic uncertainties, while signaling potential continued growth driven by the EVO+ launch and improved market conditions.

Reported metrics

Guidance from management

Management did not provide formal revenue guidance for 2026, emphasizing the need for predictability before issuing guidance. They acknowledged strong Q1 results but remain cautious about future performance due to external factors.

What management said

And our importers provide that information to us on a weekly basis. And then every month, at the end of the month, we get their inventory levels to make sure we're able to track their inventory as well.

Yes. I don't know if we've given that number explicitly. So I won't say now. But what I'll say is we have markets around the world in Japan where it's north of 50% or 60%, some even cited at 70%, depending on how you count it to some markets like the U.S., where we've only launched EVO here in the last -- since 2022, really in 2023 to commercially launch where we have a share of 3% to 5% and you have everything up to...

What analysts pressed on

Analysts expressed concerns about the lack of formal guidance for 2026 and the potential impact of geopolitical tensions on international sales. Additionally, there were questions regarding the sustainability of the strong Q1 performance and the implications of market dynamics in China.

Main topics on the call

• Strong Revenue Growth in China — China revenue reached $47.4 million in Q1, attributed to end market recovery and excitement around the EVO+ launch. Management noted, "It was a better quarter than we expected," indicating strong demand and normalized in...
• U.S. Market Performance — The U.S. market saw a 22% year-over-year growth, with quarterly sales exceeding $6 million for the first time. Management stated, "We're seeing new adoption as a result of it," highlighting the impact of marketing and su...
• Cautious Guidance — Management refrained from providing formal revenue guidance for 2026, citing the need for predictability. CFO Deborah Andrews stated, "We need to have predictability so that we have confidence to accurately and responsib...
• EVO+ Launch and Market Share — The launch of EVO+ has generated significant excitement, with management noting, "Customer excitement is real around EVO+" and indicating a premium price point that contributes to revenue growth.

Read the full STAAR Surgical Company transcript (May 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 STAAR Surgical Company earnings call transcripts on record, spanning February 26, 2020 to May 27, 2026. Based on this history, STAAR Surgical Company reports quarterly. The most recent call on file is dated May 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

STAA

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

28

First call

February 26, 2020

Most recent

May 27, 2026

Reporting cadence

quarterly